Recent Research Analysts’ Ratings Changes for Ultragenyx Pharmaceutical (RARE)

A number of research firms have changed their ratings and price targets for Ultragenyx Pharmaceutical (NASDAQ: RARE):

• 9/4/2026 – Ultragenyx Pharmaceutical had its price target lowered by The Goldman Sachs Group, Inc. from $28.00 to $19.00. They now have a “neutral” rating on the stock.
• 9/4/2026 – Ultragenyx Pharmaceutical had its price target lowered by Barclays PLC from $43.00 to $32.00. They now have an “overweight” rating on the stock.
• 9/3/2026 – Ultragenyx Pharmaceutical was downgraded by Royal Bank Of Canada from “moderate buy” to “hold”.
• 9/3/2026 – Ultragenyx Pharmaceutical had its price target lowered by Jefferies Financial Group Inc. from $77.00 to $28.00. They now have a “buy” rating on the stock.
• 9/3/2026 – Ultragenyx Pharmaceutical had its price target lowered by Citigroup Inc. from $58.00 to $28.00. They now have a “buy” rating on the stock.
• 9/3/2026 – Ultragenyx Pharmaceutical had its price target lowered by TD Cowen from $49.00 to $18.00. They now have a “buy” rating on the stock.
• 9/3/2026 – Ultragenyx Pharmaceutical was downgraded by Bank of America Corporation from “buy” to “neutral”.
• 9/3/2026 – Ultragenyx Pharmaceutical had its price target lowered by Wedbush from $30.00 to $23.00. They now have a “neutral” rating on the stock.
• 9/3/2026 – Ultragenyx Pharmaceutical had its price target lowered by Canaccord Genuity Group Inc. from $83.00 to $37.00. They now have a “buy” rating on the stock.
• 9/3/2026 – Ultragenyx Pharmaceutical was downgraded by William Blair from “outperform” to “market perform”.
• 9/3/2026 – Ultragenyx Pharmaceutical had its price target lowered by Cantor Fitzgerald from $103.00 to $33.00. They now have an “overweight” rating on the stock.
• 9/3/2026 – Ultragenyx Pharmaceutical had its price target lowered by HC Wainwright from $50.00 to $25.00. They now have a “buy” rating on the stock.
• 9/3/2026 – Ultragenyx Pharmaceutical was downgraded by Evercore Inc from “outperform” to “in-line”. They now have a $16.00 price target on the stock.
• 9/3/2026 – Ultragenyx Pharmaceutical was downgraded by Robert W. Baird from “outperform” to “neutral”. They now have a $16.00 price target on the stock, down from $40.00.
• 9/3/2026 – Ultragenyx Pharmaceutical was downgraded by JPMorgan Chase & Co. from “overweight” to “neutral”. They now have a $36.00 price target on the stock, down from $80.00.
• 9/3/2026 – Ultragenyx Pharmaceutical was downgraded by Wells Fargo & Company from “overweight” to “equal weight”. They now have a $18.00 price target on the stock, down from $50.00.
• 8/28/2026 – Ultragenyx Pharmaceutical had its price target raised by Wells Fargo & Company from $46.00 to $50.00. They now have an “overweight” rating on the stock.
• 8/25/2026 – Ultragenyx Pharmaceutical had its price target raised by JPMorgan Chase & Co. from $75.00 to $80.00. They now have an “overweight” rating on the stock.
• 8/21/2026 – Ultragenyx Pharmaceutical had its price target raised by Morgan Stanley from $67.00 to $74.00. They now have an “overweight” rating on the stock.
• 8/20/2026 – Ultragenyx Pharmaceutical had its price target raised by Canaccord Genuity Group Inc. from $81.00 to $83.00. They now have a “buy” rating on the stock.
• 8/20/2026 – Ultragenyx Pharmaceutical had its price target raised by Citigroup Inc. from $45.00 to $58.00. They now have a “buy” rating on the stock.
• 8/20/2026 – Ultragenyx Pharmaceutical had its price target raised by Wells Fargo & Company from $45.00 to $46.00. They now have an “overweight” rating on the stock.
• 8/20/2026 – Ultragenyx Pharmaceutical had its price target raised by Cantor Fitzgerald from $96.00 to $103.00. They now have an “overweight” rating on the stock.
• 8/10/2026 – Ultragenyx Pharmaceutical had its “buy” rating reaffirmed by HC Wainwright. They now have a $50.00 price target on the stock.
• 8/8/2026 – Ultragenyx Pharmaceutical was upgraded by Wall Street Zen from “sell” to “hold”.
• 8/5/2026 – Ultragenyx Pharmaceutical had its price target lowered by Wells Fargo & Company from $47.00 to $45.00. They now have an “overweight” rating on the stock.
• 8/4/2026 – Ultragenyx Pharmaceutical had its price target lowered by Guggenheim from $43.00 to $35.00. They now have a “buy” rating on the stock.

Insider Activity at Ultragenyx Pharmaceutical

In other news, Director Corazon (Corsee) D. Sanders sold 2,000 shares of the firm’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $25.05, for a total transaction of $50,100.00. Following the transaction, the director directly owned 21,095 shares of the company’s stock, valued at approximately $528,429.75. This trade represents a 8.66% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Karah Parschauer sold 1,899 shares of the company’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $24.62, for a total transaction of $46,753.38. Following the completion of the sale, the executive vice president directly owned 94,462 shares of the company’s stock, valued at $2,325,654.44. The trade was a 1.97% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 4,060 shares of company stock worth $99,106. 5.20% of the stock is owned by insiders.

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.